Work Here?
Overview
Repligen provides products and services to support biotherapeutic manufacturing. It offers filtration, chromatography systems, process analytics, fluid management, and protein solutions that help develop and produce biologics such as cell and gene therapies, mRNA, monoclonal antibodies, antibody–drug conjugates, bispecific antibodies, and fusion proteins. Its offerings are designed to fit the full bioprocess workflow—from upstream filtration and purification to downstream analytics and process control—through a portfolio of systems, consumables, and services. Repligen differentiates itself by maintaining a broad, integrated suite of bioprocessing technologies and global manufacturing support across 22 sites, enabling clients to scale from development to commercial production. The company’s goal is to advance and accelerate the manufacturing of biologics by providing reliable, end-to-end solutions that streamline development and scale-up.
About Repligen
Industries
Biotechnology
Healthcare
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Waltham, Massachusetts
Founded
1981
Get referred to Repligen
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 revenue reached $204 million, up 12%; organic growth hit 13%.
- Management raised 2026 guidance to $813 million-$835 million and EPS to $2.03-$2.09.
- BioLife deal adds immediate accretion, with 25 cents EPS expected in year two.
What critics are saying
- BioLife closing needs regulatory and shareholder approvals; failure kills the July 22, 2026 deal.
- Integration risk is real: promised $20 million first-year synergies demand clean execution by 2027.
- Thermo Fisher and Cytiva pressure pricing in consumables, threatening Repligen’s margin expansion.
What makes Repligen unique
- Repligen’s April 17, 2026 Breda center deepens customer training across bioprocess workflows.
- Its portfolio spans XCell ATF, OPUS columns, Spectrum filters, and affinity resins.
- BioLife adds 18 approved cell-therapy therapies and recurring biopreservation media relationships.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$1.1B
Above
Industry Average
Funded Over
5 Rounds
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Health Savings Account/Flexible Spending Account
Stock Price
Growth & Insights and Company News
6 month growth
↑ 27%1 year growth
↑ 27%2 year growth
↑ 27%Veralto and Repligen are two profitable stocks that face significant challenges, according to StockStory's analysis. Veralto, spun off from Danaher in 2023, has posted muted 4.6% annual revenue growth over five years, with estimated sales growth of just 6.5% for the next 12 months. The water analytics company trades at 21.8x forward P/E. Repligen, a bioprocessing technology manufacturer, has seen its adjusted operating margin fall by 16.2 percentage points over five years. Earnings per share have contracted 3.8% annually during that period, whilst returns on capital have diminished. The stock trades at 79.4x forward P/E. In contrast, Limbach, which provides building systems solutions, has delivered 15.6% annual revenue growth over two years, with earnings per share growth of 20% outpacing revenue gains.
Repligen Corporation reported second-quarter revenue of $204 million, up 12% year over year, with 13% organic growth. Adjusted earnings per share rose to $0.54 from $0.37. The company raised its full-year 2026 guidance, now expecting revenue between $813 million and $835 million, representing reported growth of 10% to 13%. Adjusted diluted EPS is projected to range from $2.03 to $2.09. Adjusted operating margin improved to 16.7% from 12.0%, reflecting stronger profitability. Management attributed the performance to continued order momentum, portfolio diversification, and disciplined execution. Repligen also highlighted its pending acquisition of BioLife Solutions, which will strengthen its position in the cell therapy market by adding a recurring consumables business with established customer relationships.
Repligen reported second-quarter profit of $5 million, or 9 cents per share. Adjusted earnings came to 54 cents per share, beating Wall Street expectations of 45 cents per share. The Waltham, Massachusetts-based drug developer posted revenue of $204.1 million in the period, surpassing analyst forecasts of $201.9 million. The company expects full-year earnings in the range of $2.03 to $2.09 per share. The results exceeded estimates from analysts surveyed by Zacks Investment Research on both earnings and revenue metrics.
WALTHAM, Mass. and BOTHELL, Wash., July 22, 2026 -- Repligen Corporation (NASDAQ: RGEN, “Repligen,” or “the Company”), a life sciences company focused on bioprocessing technology...
Repligen Corporation has agreed to acquire BioLife Solutions for approximately $1.5 billion in a deal combining cash and stock. BioLife shareholders will receive $31.00 per share, representing a 24% premium to the 90-day volume-weighted average price. The acquisition expands Repligen's presence in the cell therapy market through BioLife's biopreservation media platform, which supports 18 commercially approved therapies. The transaction is expected to be accretive, adding at least 5 cents to adjusted earnings per share in year one and 25 cents in year two. Repligen anticipates generating $20 million in synergies during year one and $30 million in year two through public-company cost eliminations and operational efficiencies. The deal will be funded with existing cash, leaving Repligen with over $300 million in pro forma cash. The transaction requires regulatory approvals and BioLife stockholder approval, with closing expected in the fourth quarter of 2026.
Repligen is Hiring for 57 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Repligen
Industries
Biotechnology
Healthcare
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Waltham, Massachusetts
Founded
1981
Repligen is Hiring for 57 Jobs on Simplify!
Find jobs on Simplify and start your career today